Aquestive Therapeutics Inc (AQST) 뉴스

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 8-K - Current report

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage...

Form 8-K - Current report

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or...

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or...

Form 8-K - Current report

Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™

Applauds first FDA approval of non-injection-based epinephrine deviceReiterates expected timing for filing of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug...

Form 8-K - Current report

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by...

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET

WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or...